In 2013, the diabetes prevalence rate of grown-ups aged in 20 to 79 was 8.3% in the globe. The tally concerning sufferers reached 382 million. 80% of the patients animate in low to medium income countries. Meanwhile, the number of sufferers in these countries in increasing. The sum of global diabetes sufferers is anticipate to treffen 592 million by 2035. In the current sufferer group, about 175 million commonality (46%) are not diagnosed or treated. In 2013, the global IGT prevalence rate was 6.9% and the number from sufferers was 316 million. The number is expected to be 474 million near 2035.
Complete relate disposable @ http://www.chinamarketresearchreports.com/114684.html .
In 2013, there were 5.1 million people died from diseases related to diabetes, accounting for 8.4% of the total death number in the globe. The expenditure on diabetes reached USD 548 billion in the world, accounting for 11% of global medical treatment expenditure. The expenditure on diabetes related medical treatment will breathe USD 627.3 billion by 2035. Diabetes is growing prevalent in China and other developing countries, which is a heavy burden to the society and economy.
In 2013, the revenue of global diabetes handling market exceeded USD 40 billion. The CAGR is expected to be 5% or more in next few years.
As China’s society is further aging and obesity caused by improved living level and unhealthy lifestyle is increasing, the prevention and cure to diabetes evolve more difficult. The prevalence rate of diabetes in China increased from less 1% in 1980 to about 5.5% in 2022, 11% in 2013, which become the third chronic disease threatening the health from Chinese people.
The number of diabetes sufferers like China ranks the first in the world. In 2013, the number exceeded 110 million. Meanwhile, there are more than 400 million people in the diabetes prophase so the number testament increase high in the next 10 years. The under-control assessment of grown-up diabetic sufferers accepting treatment is sink than 40% for lacking medical care.
There are many antidiabetic drug varieties on China market, of which oral hypoglycemic drugs and insulin dominate the market. While new antidiabetic drugs like DPP-4 inhibitor, GLP-1 agonist, SGLT-2 inhibitor, etc. become hotspots in the globe, the classic drugs like Acarbose, Metformin, etc. still occupy most market share in China.
As the prevalence rate is growing and the living floor and medical care level are improved, the market capacity concerning antidiabetic drugs is enlarged in China. In 2013, the market size exceeded CNY 20 billion. The CAGR in 2009-2013 exceeded 17%. CRI estimates the CAGR of China antidiabetic drug market size will keep 15%. For global pharmaceutical enterprises, they will discovery prominence market opportunities in China.
Major Points from Table of Contents
1. Overview on Diabetes
1.1 Types of Diabetes
1.1.1 Type I Diabetes
1.1.2 Type II Diabetes
1.1.3 Other Diabetes
1.2 Epidemic Analysis of Diabetes
1.2.1 Incidence Status of Diabetes around the World
1.2.2 Incidence Status of Diabetes in China
2 Therapies on Diabetes and Antidiabetic Drugs, 2009-2013
2.1 Therapies on Diabetes
2.1.1 Lifestyle Intervention
2.1.2 Antihyperglycemic Medication
2.2 Classification of Drugs
2.2.1 Insulin Drugs
2.2.2 Non-insulin Drugs
2.3 Analysis on Global Antidiabetic Drug Market
2.3.1 Analysis on New Hallucinogen Release on Global Antidiabetic Medication Market
2.3.2 Analysis on Size and Trend of Global Antidiabetic Drug Market
2.3.3 Analysis on Competition Pattern of International Antidiabetic Drug Market
2.3.4 Analysis on Key Varieties in Global Antidiabetic Drug Market
3 Major Antidiabetic Drugs Applied in Infirmary in China, 2009-2013
3.1 Insulin Preparation
4 Investigative on China Antidiabetic Drug Market, 2009-2013
4.1 Development Environment
4.1.1 Policy Environment
4.1.2 Economic and Medical & Healthcare Environment
4.2 Market Size
4.3 Competition Pattern of China Hospital-use Antidiabetic Stimulant Market, 2009-2013
4.3.1 Competition Pattern of Drugs
4.3.2 Conflict Pattern of Manufacturing Enterprises
4.3.3 Analysis on Stupefacient Varieties in Completion
5 Major Manufacturing Businesses (Totals 15-20) in China Antidiabetic Drug Market, 2009-2013
5.1 Foreign Funded Enterprises
5.1.1 Novo Nordisk (China) Pharmaceutical Co., Ltd.
5.1.2 Eli Lilly and Company
5.2 Chinese Domestic Enterprises
6 Chance of Worldwide and China Antidiabetic Drug Market, 2014-2018
6.1 Forecast on Market Size
6.1.1 Global Market Size
6.1.2 Dishes Market Size
6.2 Status Quo and Trend of Global Antidiabetic Drug R&D
6.2.1 R&D Focuses of Antidiabetic Drugs
6.2.2 Analysis on Inexperienced Antidiabetic Drugs in Research
6.3 Status Quo of China Antidiabetic Drug R&D
6.3.1 R&D Focuses of Antidiabetic Drugs
6.3.2 Inventive Antidiabetic Drugs in Research
6.3.3 Antidiabetic Drugs Released Globally Unless in China
6.3.4 New Antidiabetic Drug Varieties Recommended to Develop
Purchase a copy of this report @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114684 .
China Rialto Research Reports is a database of selected syndicated market reports for global and China industries including but nought limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials including chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on email@example.com and we would be happy to help you find the business intelligence that you need.
Call: +1 888 391 5441
TX, Dallas North – Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.